Ọmụmụ ihe ọhụrụ maka ọgwụgwọ nke nnukwu ọrịa leukemia myeloid

Moleculin Biotech, Inc. taa mara ọkwa na ọ natara ikike n'aka Polish Department of Registration of Medicinal Products (URPL), yana nkwado nke Kọmitii Ethics chọrọ, iji gaa n'ihu na ikpe ụlọ ọgwụ Phase 1/2 na Poland nke Annamycin (L). -ANN) yana Cytarabine (Ara-C) na ọgwụgwọ nke ndị nwere nnukwu ọrịa leukemia myeloid (AML) bụ ndị na-agbagha ma ọ bụ laghachi azụ mgbe ọgwụgwọ induction gasịrị.

Usoro 1/2 L-ANN / ARA-C nchikota (AnnAraC) nnwale (MB-106), nnwale akara ngosi, na-ewulite na nchekwa na data usoro onunu site na otu onye nnọchi anya Annamycin AML Phase 1 mezuru nke ọma (MB- 104 na MB-105) na US na Europe na data preclinical tụlere n'okpuru. A na-atụ anya na ọmụmụ ihe ahụ ga-amalite ndebanye aha onye ọrịa na ọkara mbụ nke 2022.

Walter Klemp, Onye isi oche na onye isi nchịkwa nke Moleculin kwuru, "Anyị nwere obi ụtọ na nzaghachi dị mma sitere na URPL ma nwee obi ụtọ ịme nzọụkwụ ọzọ n'ịmalite ikpe a dị mkpa. N'ịbụ ndị data agbamume a na-ahụ n'oge a kwadoro, anyị kwenyere na nchikota Annamycin na Cytarabine nwere ikike imeziwanye ihe omume megide AML. Site na ikike a iji gaa n'ihu ugbu a dị n'aka, ndị otu anyị na-arụ ọrụ iji nweta nnwale a ma na-agba ọsọ ngwa ngwa na nke ọma dị ka o kwere mee. Dabere na nkwado na-aga n'ihu na-enweta site n'aka ndị dibia bekee na Poland maka ule AnnAraC a, anyị kwenyere na anyị ga-enwe ike ịnọgide na-aga n'ihu iji nweta nnwale a na nkeji iri na ise wee wulite ngwa ngwa site na iwere ndị ọrịa. Anyị na-arụkwa ọrụ iji nwee ike ịgbasa nnwale a na mba ndị ọzọ na Europe iji nyere aka mee ka ọnụ ọgụgụ ndị ọrụ were dịkwuo elu. "

N'ụzọ dị mkpa, Annamycin egosipụtakwala enweghị cardiotoxicity n'ọtụtụ ule ụlọ ọgwụ mmadụ, gụnyere ule na-aga n'ihu maka ọgwụgwọ nke nlọghachi azụ ma ọ bụ refractory AML na soft tissue sarcoma (STS) metastases. Annamycin bụ anthracycline nke ụlọ ọrụ na-esote ọgbọ nke egosiri n'ụdị anụmanụ na-agbakọba na ngụgụ ruo okpukpu 30 n'ogo doxorubicin, yana gosipụtara ikike iji zere usoro mgbochi ọgwụ na-egbochi ịdị irè nke doxorubicin. yana anthracyclines ndị ọzọ edepụtara ugbu a. Ọzọkwa, dabere na data anụ ọhịa ndị ọzọ sitere na nyocha nkwado, Annamycin na Cytarabine gosipụtara mmụba 68% na ndụ ndụ nke etiti (OS) ma e jiri ya tụnyere Annamycin dị ka otu onye na mmụba 241% na OS ma e jiri ya tụnyere Cytarabine naanị. E gosipụtara data ndị a n'oge na-adịbeghị anya na 62nd Annual Meeting & Exposition of the American Society for Hematology ("ASH") n'okpuru aha: "High Efficacy of Liposomal Annamycin (L-ANN or Annamycin) na Nchikota na Cytarabine na Syngeneic p53-null AML Ụdị òké."

Na Jenụwarị 2022, ụlọ ọrụ ahụ kọrọ na ọ natara nyocha nchekwa onwe onye emelitere nke ụfọdụ data mbido maka ndị ọrịa 30 mbụ n'ime nnwale ụlọ ọgwụ atọ ya na Annamycin na-ezubere AML (MB-1 na MB-104) yana metastases nke nro. anụ ahụ sarcoma na ngụgụ (STS Lung) ma ọ bụ MB-105, nke kwubiri na ọ dịghị ihe àmà nke cardiotoxicity. Dabere na data izizi ahụrụ na ngalaba mmụba nke ise na nke ikpeazụ nke nnwale MB-107, ụlọ ọrụ ahụ kwuru na Annamycin gosipụtara ọnụego nzaghachi zuru oke (ORR) nke 105%. Nke a gụnyere nzaghachi akụkụ abụọ (PRs) na otu nzaghachi zuru oke na mgbake na-ezughị ezu nke neutrophils na/ma ọ bụ platelet (CRi). Mgbe iruru RP60D nke 2 mg/m240 n'enweghị nsogbu na nnwale MB-2, Ụlọ ọrụ ahụ kwubiri mbanye maka ikpe ahụ.